Wenqi Zhang Chen Huang Ruixia Liu Huichao Zhang Weijing Li Shaoning Yin Lianjing Wang Wei Liu Lihong Liu
10.3389/fimmu.2022.983934
Front Immunol
2022 Oct 5;13:983934.
btk inhibitor cd19 car-t cell therapy pd-1 antibody scnsl tislelizumab zanubrutinib
CC BY
https://pubmed.ncbi.nlm.nih.gov/36275715/
Central Nervous System Neoplasms / pathology Central Nervous System Neoplasms / therapy Lymphoma, Large B-Cell, Diffuse / pathology Neoplasms, Second Primary Receptors, Chimeric Antigen
Central Nervous System Neoplasms / pathology Central Nervous System Neoplasms / therapy Lymphoma, Large B-Cell, Diffuse / pathology Neoplasms, Second Primary Receptors, Chimeric Antigen Case Reports Research Support, Non-U.S. Gov't Antigens, CD19 Cell- and Tissue-Based Therapy Central Nervous System Clinical Trials as Topic Female Humans Neoplasm Recurrence, Local / drug therapy Programmed Cell Death 1 Receptor Protein Kinase Inhibitors / therapeutic use Antigens, CD19 Programmed Cell Death 1 Receptor Protein Kinase Inhibitors Receptors, Chimeric Antigen
PMC9581047
36275715
Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma
2022